Pityriasis rosea (PR) is an acute, self-limiting exanthematous disease associated with the endogenous systemic reactivation of human herpesvirus (HHV)-6 and/or HHV-7. The disease typically begins with a single, erythematous plaque followed by a secondary eruption with lesions on the cleavage lines of the trunk (configuration of a ‘Christmas tree'). The duration may vary from 2 weeks to a few months. Besides the typical presentation of PR, atypical forms have been described. The previous classifications of PR are mainly based on its atypical morphological features rather than on the pathogenetic mechanisms that underlie the different presentations of the disease. Notably, most of the morphologically atypical forms follow a course amenable to the classic form. The classification that we propose, taking into account the pathogenesis, clinical features, and course of the disease, is easy and intuitive and may be helpful in identifying the atypical forms of PR in order to avoid misdiagnosis and establish the best treatment options. Finally, this classification provides indications for managing potentially harmful forms of PR (such as PR in pregnancy) and PR-like eruptions.

Keywords:
Human herpesvirus-6/7, Pityriasis rosea, Classification
1.
Drago F, Ranieri E, Malaguti F, Losi E, Rebora A: Human herpesvirus 7 in pityriasis rosea. Lancet 1997;349:1367-1368.
2.
Drago F, Ranieri E, Malaguti F, Battifoglio ML, Losi E, Rebora A: Human herpesvirus 7 in patients with pityriasis rosea. Electron microscopy investigations and polymerase chain reaction in mononuclear cells, plasma and skin. Dermatology 1997;195:374-378.
3.
Watanabe T, Nakamura K, Jacob SE, Aquilino EA, Orestein JM, Black JB, Blauvelt A: Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. J Invest Dermatol 2002;119:793-797.
4.
Broccolo F, Drago F, Careddu AM, Foglieni C, Turbino L, Cocuzza CE, Gelmetti C, Lusso P, Rebora A, Malnati MS: Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol 2005;124:1234-1240.
5.
Drago F, Broccolo F, Rebora A: Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol 2009;61:303-318.
6.
Tay YK, Goh CL: One-year review of pityriasis rosea at the National Skin Centre, Singapore. Ann Acad Med Singapore 1999;28:829-831.
7.
Chuang TY, Ilstrup DM, Perry HO, Kurland LT: Pityriasis rosea in Rochester, Minnesota: 1969 to 1978. J Am Acad Dermatol 1982;7:80-89.
8.
Harman M, Aytekin S, Akdeniz S, Inaloz HS: An epidemiological study of pityriasis rosea in the Eastern Anatolia. Eur J Epidemiol 1998;14:495-497.
9.
Chuh AA, Dofitas BL, Comisel GG, Reveiz L, Sharma V, Garner SE, et al: Interventions for pityriasis rosea. Cochrane Database Syst Rev 2007;2:CD005068.
10.
Bjornberg A, Hellgren L: Pityriasis rosea. A statistical, clinical, and laboratory investigation of 826 patients and matched healthy controls. Acta Derm Venereol Suppl (Stockh) 1962;42(suppl 50):1-68.
11.
Chuh A, Zawar V, Lee A: Atypical presentations of pityriasis rosea: case presentations. J Eur Acad Dermatol Venereol 2005;19:120-126.
12.
Drago F, Ciccarese G, Rebora A, Parodi A: Pityriasis rosea and pityriasis rosea-like eruption: can they be distinguished? J Dermatol 2014;41:864-865.
13.
Drago F, Ciccarese G, Rebora A, Parodi A: Relapsing pityriasis rosea. Dermatology 2014;229:316-318.
14.
Drago F, Broccolo F, Ciccarese G, Rebora A, Parodi A: Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. Dermatology 2015;230:23-26.
15.
Drago F, Ciccarese G, Broccolo F, Cozzani E, Parodi A: Pityriasis rosea in children: clinical features and laboratory investigations. Dermatology 2015;231:9-14.
16.
Klauder JV: Pityriasis rosea with particular reference to its unusual manifestations. JAMA 1924;82:178-183.
17.
Percival GH: Pityriasis rosea. Br J Dermatol 1932;44:241-253.
18.
Drago F, Vecchio F, Rebora A: Use of high-dose acyclovir in pityriasis rosea. J Am Acad Dermatol 2006;54:82-85.
19.
Gibney MD, Leonardi CL: Acute papulosquamous eruption of the extremities demonstrating an isomorphic response. Inverse pityriasis rosea (PR). Arch Dermatol 1997;133:654.
20.
Zawar V, Godse K: Annular groin eruptions: pityriasis rosea of Vidal. Int J Dermatol 2011;50:195-197.
21.
Eslick GD: Atypical pityriasis rosea or psoriasis guttata? Early examination is the key to a correct diagnosis. Int J Dermatol 2002;41:788-791.
22.
Zawar V, Chuh A: Follicular pityriasis rosea. A case report and a new classification of clinical variants of the disease. J Dermatol Case Rep 2012;6:36-39.
23.
Halkier-Sørensen L: Recurrent pityriasis rosea. New episodes every year for five years. A case report. Acta Derm Venereol 1990;70:179-180.
24.
Zawar V, Kumar R: Multiple recurrences of pityriasis rosea of Vidal: a novel presentation. Clin Exp Dermatol 2009;34:e114-e116.
25.
Dunmire SK, Hogquist KA, Balfour HH: Infectious mononucleosis. Curr Top Microbiol Immunol 2015;390:211-240.
26.
Hall CB, Long CE, Schnabel KC, Caserta MT, McIntyre KM, Costanzo MA, Knott A, Dewhurst S, Insel RA, Epstein LG: Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994;331:432-438.
27.
Vidimos AT, Camisa C: Tongue and cheek: oral lesions in pityriasis rosea. Cutis 1992;50:276-280.
28.
Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T, Kajita Y, Ozaki T: Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics 1994;93:104-108.
29.
Jacyk WK: Pityriasis rosea in Nigerians. Int J Dermatol 1980;19:397-399.
30.
Corson EF, Luscombe HA: Coincidence with pityriasis rosea with pregnancy. AMA Arch Derm Syphilol 1950;62:562-564.
31.
Drago F, Broccolo F, Zaccaria E, Malnati M, Cocuzza C, Lusso P, Rebora A: Pregnancy outcome in patients with pityriasis rosea. J Am Acad Dermatol 2008;58:S78-S83.
32.
Drago F, Broccolo F, Javor S, Drago F, Rebora A, Parodi A: Evidence of human herpesvirus-6 and -7 reactivation in miscarrying women with pityriasis rosea. J Am Acad Dermatol 2014;71:198-199.
33.
Drago F, Broccolo F, Agnoletti A, Drago F, Rebora A, Parodi A: Pityriasis rosea and pityriasis rosea-like eruptions. J Am Acad Dermatol 2014;70:196.
34.
Drago F, Ciccarese G, Javor S, Parodi A: Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature. J Eur Acad Dermatol Venereol 2016;30:544-545.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.